Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 09, 2021 / 09:10PM GMT
Release Date Price: $41.82 (+6.47%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Hello, everyone. Thank you for joining our Second Virtual Health Care Conference. My name is Gena Wang. I'm Senior Analyst at the Barclays. First, I wish everyone, stay healthy, and I would like to thank all the participants, investors, companies and especially the event team and corporate access team who made this virtual health care conference possible. With that, I would like to introduce our next presenting companies REGENXBIO.

Today with us, we have Steve Pakola, Chief Medical Officer; Olivier Danos, Chief Scientific Officer. So with that, maybe I hand over to you, Steve, to give a few minute high-level description over the company and then we can go to the Q&A.

Stephen Pakola
REGENXBIO Inc. - Chief Medical Officer

Sure. Sounds great. First, Gena, thanks for having Olivier and I here. We're very excited about our progress across our platform programs.

So it's a great opportunity to always to sit down with you and have some Q&A across those programs. So the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot